Stewart ZA, et al. - Researchers scrutinized the safety, efficacy, and longer-term feasibility of day-and-night closed-loop insulin delivery in type 1 diabetes (T1D) pregnant women. Less nocturnal hypoglycemia (2300–0700 h) during closed-loop therapy and a trend toward higher overnight time in the target were illustrated. Data shed light on the link between closed-loop insulin delivery with comparable glucose control and markedly less hypoglycemia compared to sensor-augmented pump (SAP) therapy.